INSIDER
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources

Public disclosures only. Scores flag unusual patterns and are not evidence of wrongdoing. Not investment advice.

RH CHAIN…
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
01Overview02Follow the Money03Daily Brief04Live05Congress06Corporate Insiders07Government Money08Political Influence09Institutions10Washington Network11Follow the Power12Disclosure Clock13AI Investigator14Watchlist
ConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
OverviewFollow the MoneyDaily BriefLiveCongressCorporate InsidersGovernment MoneyPolitical InfluenceInstitutionsWashington NetworkFollow the PowerDisclosure ClockAI InvestigatorWatchlistConvergenceINSIDER AlphaSignal ledgerHistorical ReplayRobinhood ChainProofTradingTokenProAccountMethodologyMatch reviewLaunch readiness
Data sources
SEC FORM 42h ago
HOUSE PTR2h ago
SEC 13F2h ago
ROBINHOOD CHAIN2h ago
SEC FORM 4/Grant or awardVerified data

Smeal Tod reported CRDF

Chief Scientific Officer · Cardiff Oncology, Inc. · Cardiff Oncology, Inc. — Stock Options

Side
A
Value
—
Shares
300.0K
Price
—
Executed
Apr 14, 2026
Disclosed
Apr 16, 2026
Disclosure timeline2 days from execution to publication · legal deadline 2 business days
Apr 14 executedApr 16, 2026 disclosed

CRDF · daily

Yahoo Finance chart API
▲Execution▼Disclosure●Material company filing●Other disclosed buy●Other disclosed sellUnofficial public endpoint; daily OHLCV, split-adjusted. Replace with a licensed feed for production.

Insider Score

Experimental signal
17/ 100 · ROUTINE
Methodology →
  • Transaction type0 / 20

    Grant or award — administrative, little informational value

  • Relative size+9 / 25

No reported dollar value · 30.6% of prior position

  • Filing timing0 / 15

    Disclosed 2 business days after execution (deadline: 2)

  • Historical behavior+8 / 15

    First recorded trade by this actor in this security

  • Frequency & clustering0 / 15

    No clustered activity in the dataset

  • Market events0 / 10

    No material company filing within 60 days after the trade

  • The Insider Score measures how far a disclosure deviates from normal filing patterns. A high score is a prompt for research, not evidence of illegal insider trading.

    Other disclosed activity · CRDF

    ScoreActorSecuritySideValueExecutedDisclosedLagSourceEvidence
    9
    AA
    Aggarwal AjayChief Operating Officer
    CRDFCardiff Oncology, Inc.
    Grant or award
    A—
    400.0K sh
    Apr 27, 2026Apr 28, 2026
    traded Apr 27, 2026
    +1dSEC FORM 4

    Evidence

    23
    LU
    Lindsay Brigitte UteChief Accounting Officer
    CRDFCardiff Oncology, Inc.
    Grant or award
    A—
    200.0K sh
    Feb 13, 2026Feb 18, 2026
    traded Feb 13, 2026
    +5dSEC FORM 4

    Evidence

    Evidence

    Verified data

    Read directly from the primary public document; every field below is as reported by the filer.

    Source

    Document
    SEC Form 4
    Publisher
    U.S. Securities and Exchange Commission (EDGAR)
    Document ID
    0001904824-26-000002
    Machine-readable
    Structured copy

    Timestamps

    Event (reported)
    Apr 14, 2026
    Published
    Apr 16, 2026
    Ingested by INSIDER
    Nov 5, 04:04 UTC
    Last re-read
    Nov 5, 04:04 UTC

    Extracted facts

    Filer
    Smeal Tod
    Role
    Chief Scientific Officer
    Transaction
    Grant or awardAs filed: “A”
    Asset
    Cardiff Oncology, Inc. — Stock Options
    Ticker
    CRDF
    Shares
    300.0K
    Price per share
    $0
    Execution date (reported)
    Apr 14, 2026
    Owned after transaction
    1.28M shares
    Days from execution to publication
    2

    What this establishes

    Smeal Tod filed this Form 4 reporting a grant or award of CRDF on Apr 14, 2026. It became public on Apr 16, 2026. The filing establishes the reported transaction and the filer's stated role. It does not establish why the trade was made or what the filer knew.

    Extraction

    Method
    Form 4 XML
    Confidence
    1.00
    Chief Scientific Officer
    Smeal Todcik:0001904824
    Issuer
    Cardiff Oncology, Inc.cik:0001213037

    Revision history · 0

    No field has changed since this record was first ingested.

    Company events

    No records

    No material filings recorded for this issuer.